Skip to main content

Table 3 Incidence of treatment-related adverse events of two treatment regimens during preoperative treatment

From: Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study

Adverse events

SOX + apatinib (N = 21)

SOX (N = 29)

P value

Any grade, n (%)

Grade 3/4, n (%)

Any grade, n (%)

Grade 3/4, n (%)

Neutropenia

9 (42.9%)

3 (14.3%)

11 (37.9%)

4 (13.8%)

0.731

Leukopenia

7 (33.3%)

2 (9.5%)

9 (31.0%)

3 (10.3%)

0.712

Thrombocytopenia

3 (14.3%)

1 (4.8%)

4 (13.8%)

2 (6.9%)

0.673

Hypertension

4 (19.0%)

1 (4.8%)

0

0

0.777

Hand-foot syndrome

4 (19.0%)

1 (4.8%)

0

0

0.777

Oral mucositis

5 (23.8%)

0

0

0

0.915

Vomiting

10 (47.6%)

2 (9.5%)

14 (48.3%)

3 (10.3%)

0.667

Peripheral neuropathy

3 (14.3%)

0

5 (17.2%)

0

0.600

Fatigue

4 (19.0%)

1 (4.8%)

6 (20.7%)

1 (3.4%)

0.600